Retirement Guys Formula LLC Purchases Shares of 5,753 AbbVie Inc. $ABBV

Retirement Guys Formula LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 3rd quarter, HoldingsChannel reports. The fund acquired 5,753 shares of the company’s stock, valued at approximately $1,332,000.

Several other institutional investors have also recently added to or reduced their stakes in ABBV. Conning Inc. lifted its position in AbbVie by 7.1% during the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after buying an additional 12,690 shares during the period. Diversified Trust Co lifted its holdings in shares of AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after acquiring an additional 10,891 shares during the period. Dohj LLC boosted its position in shares of AbbVie by 41.8% in the second quarter. Dohj LLC now owns 4,529 shares of the company’s stock worth $802,000 after acquiring an additional 1,335 shares during the last quarter. Permanent Capital Management LP purchased a new stake in AbbVie in the third quarter valued at approximately $720,000. Finally, First Hawaiian Bank increased its position in AbbVie by 0.8% during the second quarter. First Hawaiian Bank now owns 7,556 shares of the company’s stock worth $1,403,000 after purchasing an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 0.3%

Shares of AbbVie stock opened at $229.26 on Friday. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a market cap of $405.19 billion, a price-to-earnings ratio of 173.68, a price-to-earnings-growth ratio of 0.96 and a beta of 0.36. The company has a fifty day moving average price of $226.69 and a 200 day moving average price of $213.74.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the firm posted $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Piper Sandler reiterated an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. HSBC raised AbbVie from a “hold” rating to a “buy” rating and increased their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. JPMorgan Chase & Co. lifted their target price on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.